Optimum NordiQC test results for Nordic BioSite Optibodies™

The ratings were gained in external IHC quality assessments, produced by NordiQC (Nordic Immunohistochemical Quality Control), the independent scientific organization that promotes the quality and standardization of immunohistochemistry. NordiQC arranges schemes for pathology laboratories, assessing tissue-based assays, giving guidelines for improvement and providing optimal protocols.

Clinically important

Nordic BioSite Our experts have continuously been working with new, clinically important markers and antibodies. Our laboratory takes part in external quality assurance programs for immunohistochemistry. Immunohistochemical protocols with Optibodies™ have again been awarded excellent results in NordiQC schemes. We would like to promote the standardization and quality of immunohistochemistry of our laboratory with Optibodies™, which fulfill the optimal staining criteria of immunohistochemistry according to the NordiQC assessments.

The latest series of NordiQC test schemes (runs) produced impressive results with eight antibodies from the Optibodies™ range:

Optimum results

NordiQC Runs 41 and run 47 proved CKpan (Clone BS5) as a broad-spectrum cytokeratin antibody optimized for carcinoma diagnostics, offering strong intensity with no background and unspecific label.

Run 43 produced favorable results for Synaptophysin (Clone BS15). In neuroendrocrine tumor and control tissue of appendix (neuronal cells in muscularis propria of appendix), showing specific staining with strong and intensive label, along with high intensity staining of goblet cells in crypts of appendix epithelia.

Run 44 showed a similar result for Napsin A (Clone BS10), which is used as a differential marker of the lung adenocarcinoma vs. squamous cell carcinoma., again producing excellent staining specificity and intensity.

Run 45 produced good news about two different Optibodies in assessment: EpCAM (BS14) and SOX10 (BS7). EpCAM’s high-quality performance was proved with different staining platforms, demonstrating the advantages of alkaline antigen retrieval in offering optimal staining pattern without special antigen retrieval buffers. The same run also demonstrated SOX10 (BS7) as an impressive addition for melanoma diagnostics, effectively marking desmoplastic and spindle cell melanoma with strong intensity and no noise.

The following test (Run 46) again produced favorable results for two Optibodies, CD34 (BS72) and CK5 (BS42), while the final Run 47 archived optimal broad spectrum results for Cytokeratin 20 (BS101) along with CKPan.

Rabbit monoclonal Optibodies

Nordic BioSite has also announced its intention to expand the selection of rabbit monoclonal antibodies in the Optibodies range.

There are currently five rabbit monoclonal Optibodies, of which two have turned in excellent staining performances in recent tests: L1CAM (BSR3) for endometrial carcinoma and PD1 (BSR1) for T-cell lymphoma diagnostic.

Numerous studies have shown L1CAM to be an excellent marker for early stage endometrial carcinomas. Since L1CAM positive carcinoma predicts poor clinical outcome, typically associated with aggressive carcinomas, it is an essential component of the endometrium carcinoma panel.

PD1 is a marker of T-cell lymphomas, particularly anablastic lymphoma. The Nordic BioSite BSR1 clone Optibody offers intensive signal with specific performance.

Other rabbit monoclonal Optibodies include CD3 (BSR10), CD7 (BSR9) and P63 (BSR6).

About Nordic BioSite

Since the late 1990s, Nordic BioSite has become recognized as one of the pharma industry’s most innovative and customer-responsive supplier of high quality validated biotechnology products for research, diagnostics, immunology and molecular biology.

The company serves pharmaceutical, biotech, diagnostic and academic organizations with tens of thousands of different products in more than 30 different groups, ranging from antibodies to genetic vectors. These are sourced from selected manufacturers and laboratories in Europe, the Americas and Asia.

Nordic BioSite continuously introduces new products as a result of its own R&D, leveraged by close partnerships with manufacturers and feedback from customers.

Nordic BioSite’s company strapline, By Your Side™, defines a company ethos of partnering life science customers, helping to find the right products and services to help reach chosen goals across the whole spectrum of biotech research areas.

Nordic BioSite also operates as a CRO through its Finnish-based cGLP laboratory, BioSiteHisto. This offers a wide range of leading-edge research-based custom laboratory services including histology, immunochemistry, in vitro research and testing, antibody optimization, antibody conjugation and predesigned adenylated linkers for Next Generation sequencing.